ES2662847T3 - Formulaciones novedosas de inhalación - Google Patents

Formulaciones novedosas de inhalación Download PDF

Info

Publication number
ES2662847T3
ES2662847T3 ES14174889.7T ES14174889T ES2662847T3 ES 2662847 T3 ES2662847 T3 ES 2662847T3 ES 14174889 T ES14174889 T ES 14174889T ES 2662847 T3 ES2662847 T3 ES 2662847T3
Authority
ES
Spain
Prior art keywords
lactose monohydrate
monohydrate particles
inhalation formulations
volume
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14174889.7T
Other languages
English (en)
Inventor
Ali TÜRKYILMAZ
Devrim Celik
Onur Mutlu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arven Ilac Sanayi ve Ticaret AS
Original Assignee
Arven Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi ve Ticaret AS filed Critical Arven Ilac Sanayi ve Ticaret AS
Application granted granted Critical
Publication of ES2662847T3 publication Critical patent/ES2662847T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación en polvo seco que comprende a. un dihidrato de fumarato de 5 formoterol micronizado y budesonida micronizada y, b. monohidrato de lactosa como un portador que comprende partículas de monohidrato de lactosa finas y partículas de monohidrato de lactosa gruesas; el tamaño de partícula d0.5 por volumen de las partículas de monohidrato de lactosa finas está entre 0.5 μm y 25 μm y el tamaño de partícula d0.5 por volumen de las partículas de monohidrato de lactosa gruesas está entre 40 μm y 200 μm, caracterizado porque la densidad a granel vertida de la formulación en polvo seco está entre 0.42 g/ml y 0.57 g/ml.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES14174889.7T 2013-07-01 2014-06-30 Formulaciones novedosas de inhalación Active ES2662847T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201307891 2013-07-01
TR201307891 2013-07-01

Publications (1)

Publication Number Publication Date
ES2662847T3 true ES2662847T3 (es) 2018-04-10

Family

ID=49674361

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14174889.7T Active ES2662847T3 (es) 2013-07-01 2014-06-30 Formulaciones novedosas de inhalación

Country Status (5)

Country Link
EP (2) EP2821061B1 (es)
ES (1) ES2662847T3 (es)
PL (1) PL2821061T3 (es)
PT (1) PT2821061T (es)
TR (1) TR201802969T4 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107929257B (zh) * 2017-12-01 2019-04-16 广东一力集团制药股份有限公司 一种酒石酸阿福特罗粉吸入剂胶囊及其制备方法
WO2020240350A1 (en) * 2019-05-24 2020-12-03 Glenmark Pharmaceutical Limited An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate
EP4108230A1 (en) * 2021-06-24 2022-12-28 Laboratoires SMB New dry powder composition of tiotropium for inhalation
WO2023187393A1 (en) 2022-03-31 2023-10-05 Hovione Scientia Limited Inhalation composite and carrier based formulation combination

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
ES2192866T3 (es) * 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
KR101369631B1 (ko) * 2002-08-21 2014-03-05 노턴 헬스케어 리미티드 흡입용 조성물

Also Published As

Publication number Publication date
TR201802969T4 (tr) 2018-03-21
PT2821061T (pt) 2018-03-13
EP2821061B1 (en) 2017-12-20
PL2821061T3 (pl) 2018-05-30
EP2821062A1 (en) 2015-01-07
EP2821061A1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
ES2662847T3 (es) Formulaciones novedosas de inhalación
MX2020004171A (es) Dispositivo de suministro de aerosol.
CL2016002714A1 (es) Un inhalador articulado de cápsula
AR098640A1 (es) Inhalador de polvo seco
CL2016000028A1 (es) Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación
CL2015002632A1 (es) Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado
CL2015002787A1 (es) Formulación de acetato de abiraterona.
ES2582402T3 (es) Madera de imitación
TWD164720S (zh) 錶帶扣
AR098996A1 (es) Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina
GT201400182A (es) Formulaciones farmacéuticas novedosas
AR089805A1 (es) FORMULACION SECA EN POLVO QUE COMPRENDE UNA CORTICOESTEROIDE Y UN b-ADRENERGICO PARA ADMINISTRAR POR INHALACION
PE20171022A1 (es) Inhalador de polvo seco y mecanismo para su accionamiento por inhalacion
EA201590734A1 (ru) Вдыхаемые лекарственные средства
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
SG11201507667SA (en) Fine dry particulate retinoid active agent compositions and topical formulations including the same
BR112014011452A2 (pt) artigo abrasivo para operações de moagem de taxa de remoção de material ultra elevada
CL2016000180A1 (es) Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación
BR112014029932A2 (pt) ferramenta de corte com diâmetro pequeno
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
MY178819A (en) Methods and systems for conditioning of particulate crystalline materials
MY181226A (en) Formulation of metaxalone
ES2565637T3 (es) Método de obtención de nanocristales de fluorapatita facetados
ES2664737T3 (es) Tratamiento de enfermedades intestinales inflamatorias con clinoptilolita
TR201716207A2 (tr) Vilanterol ve umeklidinyum içeren farmasötik formülasyonlar.